Robert Chen, MD
Internal Medicine · Saint John, INNPI 1255335816
Payments from drug & device makers
Across 73 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$228
- Novo Nordisk$118
- Astellas Pharma US Inc$109
- Pacira Therapeutics, Inc.$99
- AstraZeneca$87
- Pfizer$86
- plus $486 from 21 others
What the payments were for
- Food & beverage$1,212100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 15 | $228 |
| Novo Nordisk | 8 | $118 |
| Astellas Pharma US Inc | 6 | $109 |
| Pacira Therapeutics, Inc. | 1 | $99 |
| AstraZeneca | 6 | $87 |
| Pfizer | 7 | $86 |
| Exact Sciences | 2 | $43 |
| Genentech USA, Inc. | 2 | $41 |
| Amarin Pharma, Inc. | 3 | $40 |
| Inspire Medical Systems, Inc. | 1 | $37 |
| Johnson & Johnson | 2 | $36 |
| Amgen | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $24 |
| Boston Scientific | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $23 |
| Edwards Lifesciences | 1 | $21 |
| Tonix Medicines, Inc. | 1 | $19 |
| Merck | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| GSK | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Lilly USA, LLC | 1 | $11 |
| Medtronic | 1 | $11 |
| Organon | 1 | $7 |
How this compares
$1,212 in reported general payments places this provider in the 75th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 105 | $138,103 |
| JardianceEmpagliflozin | 75 | $89,999 |
| EliquisApixaban | 85 | $69,674 |
| MounjaroTirzepatide | 42 | $45,945 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $37,524 |
| XareltoRivaroxaban | 20 | $31,755 |
| JanuviaSitagliptin Phosphate | 20 | $29,580 |
| LinzessLinaclotide | 18 | $20,237 |
| RybelsusSemaglutide | 11 | $18,620 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $14,134 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 75 | $10,440 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $9,343 |
| Humalog Kwikpen U-100Insulin Lispro | 29 | $8,914 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $7,356 |
| Atorvastatin Calcium | 907 | $6,476 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $118 | $156,723116 claims |
| Boehringer IngelheimJardiance | $14 | $89,99975 claims |
| PfizerEliquis | $86 | $69,67485 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $14 | $52,45574 claims |
| Lilly USA, LLCMounjaro | $11 | $45,94542 claims |
| Johnson & JohnsonXarelto | $36 | $31,75520 claims |
| MerckJanuvia | $18 | $29,58020 claims |
| AbbVieLinzess, Synthroid | $228 | $23,86887 claims |
| AstraZenecaSymbicort, Pulmicort Flexhaler | $87 | $7,45322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Saint John
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
- Rita SchmidSouth Bend$599K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.